Pre-clinical studies showed that sorafenib inhibited tumor cell proliferation and angiogenesis by blocking serine/threon临床前研究显示，索拉非尼作用的2种激酶会影响肿瘤细胞增生及血管生成，而此2种行为为肿瘤生长时所不可或缺。